UWACIPRO

This brand name is authorized in Nigeria.

Active ingredients

The drug UWACIPRO contains one active pharmaceutical ingredient (API):

1	Ciprofloxacin UNII 4BA73M5E37 - CIPROFLOXACIN HYDROCHLORIDE
	Ciprofloxacin is a fluoroquinolone antibacterial agent. The bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.
	Read more about Ciprofloxacin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-6655	Tablet	UWACIPRO TABLETS TAB 500 mg 1 X 10	55 CMS-PP-346878 UWACIPRO TABLETS CIPROFLOXACIN HYDROCHLORIDE BP 500MG EACH TABLET CONTAINS CIPROFLOXACIN HYDROCHLORIDE BP 500MG EXCIPIENTS CMS-PP-346858 B4-6655 Drugs Imported Products 1X10 Prescription Only Medicine (POM) 7/27/2023 SUITELIFE PHARMACEUTICALS LTD, 4 ayo davis close off ekolonu street, surulere, lagos 8129419809 suitelifepharma@yahoo.com SSM FORMULATIONS PRIVATE LIMITED, SURVEY NO. 11/1, MOUZA ASHTI, HINGANGHAT 442301, MAHARASHTRA, INDIA., India	21/12/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01MA02	Ciprofloxacin	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01M Quinolone antibacterials → J01MA Fluoroquinolones
Discover more medicines within J01MA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-6655